Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 1;44(8):852-60.
doi: 10.1038/ng.2330.

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhenfeng Zhang  1 , Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho, Yun Jung Choi, Chang-Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung-Shin Lee, Vincent A Miller, Maria Arcila, Marc Ladanyi, Philicia Moonsamy, Charles Sawyers, Titus J Boggon, Patrick C Ma, Carlota Costa, Miquel Taron, Rafael Rosell, Balazs Halmos, Trever G Bivona
Affiliations

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhenfeng Zhang et al. Nat Genet. .

Abstract

Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation. Genetic or pharmacological inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs. These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1. AXL is overexpressed in EGFR-mutant NSCLC tumor xenografts with acquired resistance to erlotinib
a, Effects of a dose-response of erlotinib in HCC827 xenograft tumors in immunocompromised mice (n=10 tumors/treatment group). b–f, mRNA expression of indicated genes in HCC827 erlotinib resistant tumor xenografts (treated at the indicated erlotinib doses) relative to vehicle-treated control tumors. The number of tumors analyzed from each treatment cohort is indicated in parentheses. Data are expressed as the mean ± SEM of the fold change relative to the mean expression of the genes in 2 vehicle treated control xenograft tumors.
Figure 2
Figure 2. AXL overexpression is necessary for acquired resistance to erlotinib treatment in EGFR-mutant NSCLC tumors in vivo
a, AXL and pAXL protein levels are increased in the absence of pEGFR and increased pMET in HCC827 tumors from each erlotinib treatment cohort compared with vehicle treated tumors. Tumors were harvested for analysis at the completion of the study for each treatment group (Vehicle: Day 45; 6.25 Erl: Day 60; 12.5 Erl: Day 110; 25 Erl: Day 110; 50 Erl: Day 100) b, Acute and transient treatment of HCC827 tumors with erlotinib (12.5 mg/kg/day) decreases pAKT, pERK, pRELa and increases the levels of cleaved Parp. c, Response of parental HCC827 xenograft tumors or HCC827 ER xenograft tumors (n= 10 tumors/group) transduced with a non-target shRNA or an shRNA targeting AXL to treatment with either vehicle or erlotinib (12.5 mg/kg/day). Tumor volumes are expressed as mean ± SEM. d, Validation of AXL knockdown and the effects of erlotinib treatment on pEGFR in representative tumor xenografts (c) by western blot analysis.
Figure 3
Figure 3. AXL upregulation is necessary and sufficient for erlotinib acquired resistance in EGFR mutant NSCLC cellular models
a, HCC827 ER1-ER5 sublines are resistant to erlotinib treatment as measured by CellTiterGLO cell viability assay. Data are from 3 independent experiments and are expressed as percent of vehicle treated cells and mean ± SEM. b, Expression of AXL and GAS6 in the ER sublines compared with parental HCC827 cells (data are from Western blot analysis). c, Erlotinib IC50 in HCC827 cell lines (as indicated) measured 48h after treatment with a non-targeting or AXL or GAS6 siRNA. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. d, Erlotinib IC50 in HCC827 cell lines (as indicated) measured 48h after treatment with vehicle (control) or with MP-470 (1 µM) or XL-880 (1 µM) and erlotinib. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. e, Effects of treatment for 48h with a non-targeting (−) or AXL siRNA in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. f–g, Effects of treatment for 48h with a vehicle or the indicated doses of (f) MP-470 or (g) XL-880 in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. h,Erlotinib IC50 in HCC827 cells measured 5 days after transfection the cDNA constructs encoding the indicated proteins and treated with either vehicle (left) or with XL-880 (1 µM) and erlotinib. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. i, Western blot for the indicated proteins in lysates from cells transfected with the indicated cDNA constructs and treated with XL-880 (1 µM) for 3 hours prior to cell lysis (h).
Figure 3
Figure 3. AXL upregulation is necessary and sufficient for erlotinib acquired resistance in EGFR mutant NSCLC cellular models
a, HCC827 ER1-ER5 sublines are resistant to erlotinib treatment as measured by CellTiterGLO cell viability assay. Data are from 3 independent experiments and are expressed as percent of vehicle treated cells and mean ± SEM. b, Expression of AXL and GAS6 in the ER sublines compared with parental HCC827 cells (data are from Western blot analysis). c, Erlotinib IC50 in HCC827 cell lines (as indicated) measured 48h after treatment with a non-targeting or AXL or GAS6 siRNA. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. d, Erlotinib IC50 in HCC827 cell lines (as indicated) measured 48h after treatment with vehicle (control) or with MP-470 (1 µM) or XL-880 (1 µM) and erlotinib. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. e, Effects of treatment for 48h with a non-targeting (−) or AXL siRNA in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. f–g, Effects of treatment for 48h with a vehicle or the indicated doses of (f) MP-470 or (g) XL-880 in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. h,Erlotinib IC50 in HCC827 cells measured 5 days after transfection the cDNA constructs encoding the indicated proteins and treated with either vehicle (left) or with XL-880 (1 µM) and erlotinib. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. i, Western blot for the indicated proteins in lysates from cells transfected with the indicated cDNA constructs and treated with XL-880 (1 µM) for 3 hours prior to cell lysis (h).
Figure 3
Figure 3. AXL upregulation is necessary and sufficient for erlotinib acquired resistance in EGFR mutant NSCLC cellular models
a, HCC827 ER1-ER5 sublines are resistant to erlotinib treatment as measured by CellTiterGLO cell viability assay. Data are from 3 independent experiments and are expressed as percent of vehicle treated cells and mean ± SEM. b, Expression of AXL and GAS6 in the ER sublines compared with parental HCC827 cells (data are from Western blot analysis). c, Erlotinib IC50 in HCC827 cell lines (as indicated) measured 48h after treatment with a non-targeting or AXL or GAS6 siRNA. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. d, Erlotinib IC50 in HCC827 cell lines (as indicated) measured 48h after treatment with vehicle (control) or with MP-470 (1 µM) or XL-880 (1 µM) and erlotinib. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. e, Effects of treatment for 48h with a non-targeting (−) or AXL siRNA in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. f–g, Effects of treatment for 48h with a vehicle or the indicated doses of (f) MP-470 or (g) XL-880 in parental or ER1 and ER2 cell lines in the absence and presence of erlotinib on the indicated biomarkers. Data represent 3 independent experiments. h,Erlotinib IC50 in HCC827 cells measured 5 days after transfection the cDNA constructs encoding the indicated proteins and treated with either vehicle (left) or with XL-880 (1 µM) and erlotinib. Erlotinib IC50 is shown in parentheses. Data are representative of 3 independent experiments. i, Western blot for the indicated proteins in lysates from cells transfected with the indicated cDNA constructs and treated with XL-880 (1 µM) for 3 hours prior to cell lysis (h).
Figure 4
Figure 4. AXL-mediated erlotinib resistance occurs in association with EMT in EGFR-mutant NSCLC cellular models
a, Effects of treatment with a non-targeting or the indicated vimentin siRNAs on AXL expression in HCC827 ER3 cells. b, Erlotinb IC50 in HCC827 parental or ER3 cells upon treatment with a non-targeting or the indicated vimentin siRNAs. Erlotinib IC50 is shown in parentheses. Data represent 3 independent experiments. c, Increased migration through a transwell chamber of ER3 compared to parental HCC827 cells in cells treated with a non-targeting or the indicated vimentin (VIM) or AXL siRNAs or XL-880 (1 µM); n=3, data expressed as mean ± SEM. d, Increased adherence to plastic of HCC827 ER3 cells compared to HCC827 parental cells in cells treated with a non-targeting or the indicated vimentin (VIM) or AXL siRNAs or XL-880 (1 µM). 5 100× microscopic fields per cell line were counted. n=3, data expressed as mean ± SEM. e, Western blot for the indicated proteins in lysates from cells transfected with the indicated siRNAs in (c–d).
Figure 4
Figure 4. AXL-mediated erlotinib resistance occurs in association with EMT in EGFR-mutant NSCLC cellular models
a, Effects of treatment with a non-targeting or the indicated vimentin siRNAs on AXL expression in HCC827 ER3 cells. b, Erlotinb IC50 in HCC827 parental or ER3 cells upon treatment with a non-targeting or the indicated vimentin siRNAs. Erlotinib IC50 is shown in parentheses. Data represent 3 independent experiments. c, Increased migration through a transwell chamber of ER3 compared to parental HCC827 cells in cells treated with a non-targeting or the indicated vimentin (VIM) or AXL siRNAs or XL-880 (1 µM); n=3, data expressed as mean ± SEM. d, Increased adherence to plastic of HCC827 ER3 cells compared to HCC827 parental cells in cells treated with a non-targeting or the indicated vimentin (VIM) or AXL siRNAs or XL-880 (1 µM). 5 100× microscopic fields per cell line were counted. n=3, data expressed as mean ± SEM. e, Western blot for the indicated proteins in lysates from cells transfected with the indicated siRNAs in (c–d).
Figure 5
Figure 5. AXL upregulation occurs in human EGFR-mutant NSCLCs with EGFR TKI acquired resistance
a–b, Representative expression of the indicated proteins by IHC in (a) case 7 and (b) case 9 shown in Table 2. IHC staining for AXL and GAS6 was scored as shown in Supplemental Figure 14. Vimentin IHC staining was scored using an established, clinically validated protocoland EGFR T790M and MET amplification were assessed by sequencing and FISH, respectively, using established assays. Scale bars indicate in (a) 100 µM and (b) 10 µM.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. - PubMed
    1. Pao W, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306–13311. - PMC - PubMed
    1. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004;350:2129–2139. - PubMed
    1. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–1167. d. - PubMed
    1. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov. 2009;8:709–723. - PubMed

Publication types

MeSH terms

Associated data